Your browser doesn't support javascript.
loading
Effectiveness of the Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters in Pregnant Persons Who Were Not Immunocompromised: VISION Network, June 2022-August 2023.
Avrich Ciesla, Allison; Lazariu, Victoria; Dascomb, Kristin; Irving, Stephanie A; Dixon, Brian E; Gaglani, Manjusha; Naleway, Allison L; Grannis, Shaun J; Ball, Sarah; Kharbanda, Anupam B; Vazquez-Benitez, Gabriela; Klein, Nicola P; Natarajan, Karthik; Ong, Toan C; Embi, Peter J; Fleming-Dutra, Katherine E; Link-Gelles, Ruth; Zerbo, Ousseny.
Affiliation
  • Avrich Ciesla A; Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Lazariu V; Eagle Health Analytics, San Antonio, Texas, USA.
  • Dascomb K; Westat, Rockville, Maryland, USA.
  • Irving SA; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, Utah, USA.
  • Dixon BE; Kaiser Permanente Center for Health Research, Portland, Oregon, USA.
  • Gaglani M; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
  • Naleway AL; Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, USA.
  • Grannis SJ; Section of Pediatric Infectious Diseases, Department of Pediatrics, Baylor Scott & White Health, Temple, Texas, USA.
  • Ball S; Department of Pediatrics, Baylor College of Medicine, Temple, Texas, USA.
  • Kharbanda AB; Department of Medical Education, Texas A&M University College of Medicine, Temple, Texas, USA.
  • Vazquez-Benitez G; Kaiser Permanente Center for Health Research, Portland, Oregon, USA.
  • Klein NP; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
  • Natarajan K; School of Medicine, Indiana University, Indianapolis, Indiana, USA.
  • Ong TC; Westat, Rockville, Maryland, USA.
  • Embi PJ; Children's Minnesota, Minneapolis, Minnesota, USA.
  • Fleming-Dutra KE; HealthPartners Institute, Minneapolis, Minnesota, USA.
  • Link-Gelles R; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, USA.
  • Zerbo O; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.
Open Forum Infect Dis ; 11(9): ofae481, 2024 Sep.
Article in En | MEDLINE | ID: mdl-39286032
ABSTRACT
Pregnant people face increased risk of severe COVID-19. Current guidelines recommend updated COVID-19 vaccination (2023-2024) for those aged ≥6 months, irrespective of pregnancy status. To refine recommendations for pregnant people, further data are needed. Using a test-negative design, we evaluated COVID-19 vaccine effectiveness against medically attended COVID-19 with COVID-19-like illness among pregnant people aged 18 to 45 years during June 2022 to August 2023. When doses were received during pregnancy, vaccine effectiveness was 52% (95% CI, 29%-67%); when received <6 months prior to pregnancy, 28% (95% CI, 11%-42%); and when received ≥6 months prior to pregnancy, 6% (95% CI, -11% to 21%). Pregnant people should stay up-to-date with recommended COVID-19 vaccination.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Open Forum Infect Dis Year: 2024 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Open Forum Infect Dis Year: 2024 Document type: Article Affiliation country: United States Country of publication: United States